www.statnews.com
How unmet patient needs are shaping the next phase of cancer research
In this episode, oncology leaders Jackson Egen of Gilead Sciences and Priti Hegde of Kite, a Gilead company, discuss how unmet patient needs are shaping
A Medsky feed for healthcare workers in the fields of hematology & oncology. Keywords include oncsky, hemesky, oncology, hematology, cancersky. Users with any of @medsky.social's heme/onc labels will be added to curation list. Posts in reverse chronological order.
Feed on BlueskyFeeds Stats
- 💙 Liked by 23 users
- 📅 Updated 12 days ago
- ⚙️ Provider graze.social
- 📈 In the last 30 days, there were 2 posts about this feed. These posts got a total of 2 likes and had 0 reposts.
Heme/Onc Likes over time
Like count prediction
The feed Heme/Onc has not gained any likes in the last month.
Feed Preview for Heme/Onc
In this podcast episode, oncology leaders Jackson Egen of Gilead Sciences and Priti Hegde of Kite, a Gilead company, discuss how unmet patient needs are shaping the next phase of cancer research.
Listen: www.statnews.com/sponsor/….
0
0
0
One of our C4 Community Advisory Council members (Michael Frierson) recently did a podcast about colorectal cancer and the warning signs in those under 45 that should be promptly followed up rather than dismissed.
youtu.be/Rnh9bSpONrk?...
0
0
0
Day 3 at #ASPHO2026 was a success! Congrats to all of today's award recipients including, Dr. #KarenEffinger, Dr. #VijaySankaran, and Dr. #PeterNewburger.
0
0
0
@greggshepard.bsky.social
about 2 hours agoTake Action in Support of Federal Research Funding - Hematology.org www.hematology.org/advoca….
hematology.org
American Society of Hematology
The world's largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases.
0
0
0
Meet Jason Worley, MD 👋
He’s passionate about compassion in medicine, strong communication, and teaching future physicians, and is starting a Hospice and Palliative Medicine fellowship this year at CU. 🌟
0
0
0
🚨 #BREAKING 🚨 The @fda.gov has approved #ruxolitinib extended-release tablets (#Jakafi XR) for use in select patients with myelofibrosis, polycythemia vera, and graft-vs-host disease.
Learn more: www.onclive.com/view/fda-….
www.onclive.com
FDA Clears Once-Daily Ruxolitinib Tablets for Myelofibrosis, Polycythemia Vera, and GVHD | OncLive
The FDA has approved a once-daily, extended-release formulation of ruxolitinib for select myelofibrosis, polycythemia vera, and graft-vs-host disease.
0
0
1
Distinct phases of immune system programming during ART-suppressed immunodeficiency virus infection www.biorxiv.org/content/1…
0
0
0
Policy shift? FDA’s quick OK for daraxonrasib may set a template: pair expedited oncology review with broader expanded access when survival signals, Breakthrough/Orphan status, and sponsor readiness align. Full breakdown → future.xsbrt.com/Oncology… Reply/save thoughts.
0
0
0
Weekend Registered Nurse (RN) MUSC Florence Inpatient Oncology - FT Days - MUSC Health Florence Medical Center Job educativ.net/jobs/job/58061...
0
0
0
❇️Best of Surgical Critical Care❇️
Watch an overview of "Operative Management of Enteral Access in Acute Care Surgery: What You Need to Know"
journals.lww.com/jtrauma/…
0
0
0
FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.”
cancerletter.com/regulato…
cancerletter.com
FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients “Patients are owed another review.” - The Cancer Letter
Disappointment hangs in the air as Replimune’s Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab in the treatment of advanced melanoma was denied again by FDA on April 10. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for […]
0
0
0
Navigating Anemia Therapy in CKD: The Role of Hypoxia-Inducible Factor Activators
bit.ly/3NOciNx (OPEN ACCESS)
0
1
0
Cómo un analizador de hematología de 200 pruebas por hora reconfigura el laboratorio clínico
Mindray BC-6800Plus 5-Part Differential Hematology Analyzer El Mindray BC-6800Plus no es solo un analizador; es un nodo de eficiencia en la cadena de diagnóstico hospitalario. Su especificación técnica…
scientificchina.com
Cómo un analizador de hematología de 200 pruebas por hora reconfigura el laboratorio clínico
Mindray BC-6800Plus 5-Part Differential Hematology Analyzer El Mindray BC-6800Plus no es solo un analizador; es un nodo de eficiencia en la cadena de diagnóstico hospitalario. Su especificación técnica revela cómo China está estandarizando la automatización de alto rendimiento. El laboratorio clínico moderno depende del caudal. El BC-6800Plus responde con 200 tests por hora y carga simultánea de hasta 100 muestras.
0
0
0
Survivin inhibition induces PD-L1 expression through cGAS stabilization and attenuates antitumor immunity www.biorxiv.org/content/1…
0
0
0
New paper in Nature Reviews Clinical Oncology led by our fellow @javierdavidben2.bsky.social !
This one is on the ATOMIC trial in colon cancer.
www.nature.com/articles/s41...
www.nature.com
Did ATOMIC really improve on the standard of care for mismatch repair-deficient colon cancer? - Nature Reviews Clinical Oncology
The ATOMIC trial has been widely celebrated as providing a positive result. However, when viewed with a lens of critical appraisal that considers issues related to overtreatment, treatment de-escalati...
0
0
0
Join more than 1,500 healthcare workers on Bluesky and add a #Medsky label to your account! Now with over 270 medical specialty labels to choose from.
Instructions below.
2
36
116
A US study finds fewer kids with acute respiratory infections received antibiotics during video visits with primary care providers than in-person visits.
Read more: ow.ly/7iLZ50YTEhq
1
1
7
FDA Grants Early Access to Daraxonrasib, New Pancreatic Cancer Drug That Extends Survival in Late-Stage Patients.
👉 Read the full story at NewsLink7.com
#Daraxonrasib #PancreaticCancer #FDA #CancerTreatment #KRAS #HealthNews #Oncology #News #WorldNews #Noticias
0
0
0
Ophthopedia Update: Efficacy, tolerability, and threshold effect of atropine eye drops for myopia control: A systematic review and dose-response meta-analysis: Atropine is an emerging therapy for myopia, yet the optimal concentration for prescription remains… #Ophthalmology #Eye #Ophthotwitter
dlvr.it
Efficacy, tolerability, and threshold effect of atropine eye drops for myopia control: A systematic review and dose-response meta-analysis
Atropine is an emerging therapy for myopia, yet the optimal concentration for prescription remains uncertain. We searched PubMed, Embase, Web of Science, Cochrane Library, World Health Organization International Clinical Trials, and ClinicalTrials.gov registry platforms. We included the randomized clinical trials (RCTs) that compared any dose of atropine against a placebo in myopic children. Among 3,566 studies assessed, we identified 33 eligible RCTs involving 6,301 children aged 4 to 18 years, with 10 different concentrations and a mean follow-up time of 19.5±12.3 months.
0
0
0
Tune into WVON 1690AM's “Dr. in the House with Dr. Terry Mason,” this Sunday, May 3, at 10 a.m., when the segment will focus on National Cancer Research Month. The guest is our Cancer Center Deputy Director VK Gadi, MD PhD, an oncologist focused on breast cancer at UI Health. bit.ly/4rS0zx8
0
0
0
Our #CellLineOfTheWeek is centrin 2 - illuminating the centrosome! 🧫✨
Our high-quality stem cell lines & plasmids are openly available to reduce the barriers to scientific discovery.
📦 Distributed by @coriellinstitute.bsky.social (cell lines) and @addgene.bsky.social (plasmids)
0
2
8
AI is rapidly reshaping cancer care, but where do we draw the line? In this episode of #OncologyUnscripted, Dr Marshall explores both the promise and the pressure of AI in oncology, from predicting treatment responses and supporting clinical trials and more!
🔗 Watch here: bit.ly/3ZDiQBg
0
0
0
A new multi-ancestry #GWAS has identified 4 novel risk loci in pediatric #AML 📈
Data presented at the 2026 AACR Annual Meeting, read our coverage here: bit.ly/3QGaZlq
#HemOnc #PedOnc
0
0
0
Androgen metabolism in prostate cancer: recent advances. Read more in #Endocrinology: bit.ly/4vUb451 #Androgens #Metabolism #Steroids @endocrinesociety.bsky.social
bit.ly
Androgen metabolism in prostate cancer: recent advances
Abstract. Androgen biosynthesis is physiologically necessary for generating the principal stimulus for androgen receptor (AR) signaling and thus plays an e
0
0
0